Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals.
Namiki IzumiTetsuo TakeharaKazuaki ChayamaHiroshi YatsuhashiKoichi TakaguchiTatsuya IdeMasayuki KurosakiYoshiyuki UenoHidenori ToyodaSatoru KakizakiYasuhito TanakaYoshiiku KawakamiHirayuki EnomotoFusao IkedaDeyuan JiangShampa De-OertelBrian L McNabbGregory CamusLuisa M StammDiana M BrainardJohn G McHutchisonSatoshi MochidaMasashi MizokamiPublished in: Hepatology international (2018)
Sofosbuvir-velpatasvir plus ribavirin was highly effective and well tolerated in Japanese patients who previously failed a DAA-based regimen. Baseline NS5A RASs did not affect treatment outcomes.